EUVIMEDEuropean Health Evidence
Uhr Sources10/10 Journal Tree
Easy Demo

European Health Evidence

The European alternative to PubMed

EUVIMED is the European alternative to PubMed: a central, multilingual research platform for medicine, nursing, life sciences and healthcare. It brings together international and European literature sources, study registries, open-access full texts, citations and retraction notices in one search. Unlike pure bibliographic databases, EUVIMED supports the entire research process – from discovery and appraisal with LIVIA and CLARA to traceable evidence synthesis. European in focus, transparent, interoperable and designed for science and healthcare.

EuropeanMultilingualInteroperableTraceable

EUVIMED BETA

EUVIMED is currently in beta

EUVIMED is under continuous development. Features, data coverage and presentation may change or be temporarily incomplete.

Results are beta

Search results, classifications, summaries and AI-assisted assessments may be incomplete, delayed or incorrect.

Check original sources

Do not use EUVIMED results without verification for diagnosis, treatment or other clinical decisions. Always consult the original source and applicable guidelines.

Errors and feedback help us improve EUVIMED: info@euvimed.com

Lokaler Crossref-Datenbestand · journal-article

A truncating ELF4 variant in a pediatric patient with autoinflammatory disease and cell type-specific immune alterations

Qianlu Zhang, Yatang Lei, Lina Zhou, Zhiyong Zhang, Xuemei Tang, Yunfei An, Xiaodong Zhao, Hongqiang Du

Frontiers in Immunology · 2026

Vollständiger Abstract

Worum geht es in dieser Arbeit?

Introduction ELF4 is an ETS family transcription factor involved in immune regulation, including antiviral responses and inflammatory signaling. Germline loss-of-function variants in ELF4 cause deficiency in ELF4, X-linked (DEX), a disorder characterized by recurrent mucocutaneous inflammation and variable immune abnormalities. To date, ELF4-related disease has been reported only in association with germline mutations. Here, we report a pediatric patient with autoinflammatory disease harboring a truncating ELF4 variant (c.239T>A, p.L80*). Methods Clinical and genetic evaluations were performed in the patient and his family. The ELF4 c.239T>A variant was assessed by Sanger sequencing in peripheral blood and buccal mucosa samples. ELF4 protein expression was examined in patient-derived cells and ectopic expression of wild-type and mutant ELF4 constructs in HEK293T cells by immunoblotting. Full-length single-cell RNA sequencing was performed on whole-blood leukocytes to compare mutant-assigned and wild-type-assigned immune cells within the same individual. Results An ELF4 truncating variant (c.239T>A, p.L80*) was detected in peripheral blood but was not detected in parental blood samples or the patient’s buccal mucosa by Sanger sequencing. Given the limited sensitivity of Sanger sequencing, the developmental origin and tissue distribution of the variant could not be definitively determined. A reduced full-length ELF4 signal was observed in patient-derived PBMCs and in the p.L80* HEK293T overexpression system, together with impaired transcriptional activity in an IFN-β promoter reporter assay. Single-cell transcriptomic analysis identified cells with p.L80*-supporting transcripts across multiple immune lineages and suggested cell type-specific transcriptional alterations. Pathway analyses indicated reduced antiviral and interferon-related programs in mutant-assigned NK cells. Exploratory analysis of mutant-assigned CD16 + monocytes also suggested inflammation-related pathway alterations, although the limited number of allele-informative cells warrants cautious interpretation. Conclusions ELF4 is an ETS family transcription factor that plays an important role in immune regulation. Our study identifies a functionally impaired ELF4 p.L80* variant in a pediatric patient with autoinflammatory disease and provides preliminary evidence of cell type-specific transcriptional alterations associated with this variant.

Bibliografischer Nachweis

Publikationsdaten

Autor:innen
Qianlu Zhang, Yatang Lei, Lina Zhou, Zhiyong Zhang, Xuemei Tang, Yunfei An, Xiaodong Zhao, Hongqiang Du
Quelle
Frontiers in Immunology
Publikation
2026-01-01
Band / Ausgabe
Nicht angegeben
Seiten
Nicht angegeben
ISSN / ISBN
1664-3224
Zitationen
0 laut Crossref
Referenzen
0 hinterlegt

Zitieren

Zitierfähiger Nachweis

Qianlu Zhang, Yatang Lei, Lina Zhou, Zhiyong Zhang, Xuemei Tang, Yunfei An, Xiaodong Zhao, Hongqiang Du (2026). A truncating ELF4 variant in a pediatric patient with autoinflammatory disease and cell type-specific immune alterations. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2026.1859084
RIS BibTeX CSL-JSON

Kontext

Themen, Förderung und Nutzung

Lizenzhinweise: Lizenz 1